Physician profile
Shelle Barber
NPI 1750580262
$3,990.19
in general payments reported to CMS, 2019-2025
36 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $338 · 2021: $284 · 2022: $541 · 2023: $1,047 · 2024: $989 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.21 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Lilly USA, LLC | $435.42 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.17 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $254.09 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $240.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $220.66 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $189.38 | 2022-2025 | |
| Allergan, INC. | $184.06 | 2019-2020 | |
| Abbott Laboratories | $177.81 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $157.16 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.69 | 2019-2024 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $102.96 | 2019-2022 | |
| Glaxosmithkline, LLC. | $100.78 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $65.99 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $61.79 | 2022-2023 | Quviviq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.86 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $45.17 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $42.85 | 2019-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $34.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $32.19 | 2019-2023 | Dificid |
| Dexcom, INC. | $31.98 | 2022-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $27.86 | 2022 | |
| Seqirus USA INC | $21.28 | 2019 | |
| Tris Pharma INC | $20.59 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.04 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.57 | 2025 | Voquezna |
| Medtronic USA, INC. | $17.40 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.97 | 2022 | |
| Althera Pharmaceuticals LLC | $15.94 | 2021 | |
| Sanofi Pasteur INC. | $14.46 | 2019 | |
| Amgen INC. | $14.24 | 2025 | Repatha, Otezla |
| Echosens North America, INC. | $14.23 | 2025 | Fibroscan |
| Shire North American Group INC | $12.90 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.87 | 2020 | |
| Genentech USA, INC. | $12.20 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelle Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.